when does the patent on tirzepatide expire In weight loss battle, Novo and Lilly face growing offensive from licensed copies Eli Lilly boss reports progress

A visual diagnosis: lipodystrophy

15 Feb 2026 Tirzepatide Superior to Semaglutide in Weight Reduction Tirzepatide proves superior to semaglutide in weight reduction and improving glycaemic indices, a 2026 network meta-analysis has found

This supports overall bodily functions, can help manage appetite, and minimizes potential medication-related side effects like constipation

Lavalle-Cobo A, Masson W, Lobo M, Masson G, Molinero G (2021) Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis

Saxenda and Thyroid Cancer The Label (PDF) on Saxenda carries a Black Box to warn patients that it is known to cause thyroid C-cell tumors in mice and rats at clinically relevant exposure levels